- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02063997
Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients
January 25, 2018 updated by: CymaBay Therapeutics, Inc.
A Randomized, Double-Blind, Active and Placebo-Controlled Study to Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients
The purpose of this study is to determine whether arhalofenate is effective in preventing flares and reducing serum uric acid in gout patients.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
248
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Newmarket, Ontario, Canada
-
Sarnia, Ontario, Canada
-
Toronto, Ontario, Canada
-
-
-
-
-
Tbilisi, Georgia
-
-
-
-
Alabama
-
Birmingham, Alabama, United States
-
-
Arizona
-
Scottsdale, Arizona, United States
-
Tucson, Arizona, United States
-
-
Arkansas
-
Little Rock, Arkansas, United States
-
-
California
-
El Cajon, California, United States
-
Long Beach, California, United States
-
Los Angeles, California, United States
-
-
Colorado
-
Denver, Colorado, United States
-
-
District of Columbia
-
Washington, District of Columbia, United States
-
-
Florida
-
Clearwater, Florida, United States
-
DeLand, Florida, United States
-
Jupiter, Florida, United States
-
New Port Richey, Florida, United States
-
Orlando, Florida, United States
-
Palm Harbor, Florida, United States
-
Saint Petersburg, Florida, United States
-
Tampa, Florida, United States
-
-
Hawaii
-
Honolulu, Hawaii, United States
-
-
Idaho
-
Boise, Idaho, United States
-
-
Indiana
-
Brownsburg, Indiana, United States
-
-
Kentucky
-
Bowling Green, Kentucky, United States
-
Elizabethtown, Kentucky, United States
-
Louisville, Kentucky, United States
-
Owensboro, Kentucky, United States
-
-
Maryland
-
Hagerstown, Maryland, United States
-
-
Mississippi
-
Olive Branch, Mississippi, United States
-
-
Missouri
-
Saint Louis, Missouri, United States
-
-
Montana
-
Missoula, Montana, United States
-
-
Nebraska
-
Omaha, Nebraska, United States
-
-
New York
-
Brooklyn, New York, United States
-
New York, New York, United States
-
-
North Carolina
-
Charlotte, North Carolina, United States
-
Greensboro, North Carolina, United States
-
Hickory, North Carolina, United States
-
Raleigh, North Carolina, United States
-
Salisbury, North Carolina, United States
-
Winston-Salem, North Carolina, United States
-
-
Ohio
-
Cincinnati, Ohio, United States
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States
-
-
Oregon
-
Portland, Oregon, United States
-
-
Pennsylvania
-
Johnstown, Pennsylvania, United States
-
Wyomissing, Pennsylvania, United States
-
-
South Carolina
-
Charleston, South Carolina, United States
-
Greer, South Carolina, United States
-
Summerville, South Carolina, United States
-
-
Tennessee
-
Bristol, Tennessee, United States
-
Jackson, Tennessee, United States
-
-
Texas
-
Houston, Texas, United States
-
-
Utah
-
Salt Lake City, Utah, United States
-
West Jordan, Utah, United States
-
-
Washington
-
Spokane, Washington, United States
-
-
West Virginia
-
Clarksburg, West Virginia, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 73 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female patients between 18 and 75 years of age, inclusive
- Known gout diagnosis (per criteria of the American Rheumatism Association for the classification of the acute arthritis of primary gout, see Appendix 3)
- At least three patient-reported and documented flares during the 12 months prior to screening (the first of these flares may have resulted in the gout diagnosis; any recent flare must have resolved, with the patient back to usual comfort level at least seven days prior to screening)
- Have not used any ULT since at least two weeks prior to screening
- Have not used colchicine since at least two weeks prior to screening
- Usual level of resting pain when NOT experiencing flare is three or less on an 11-point numerical rating scale (NRS)
- Have a sUA ≥ 7.5 mg/dL and ≤ 12 mg/dL at screening
- All female patients must be surgically sterile or post-menopausal (at least 45 years of age with no history of menses for at least two years); or have a partner who has undergone vasectomy or must agree to use two medically accepted methods of contraception including a barrier method (see Appendix 4) for the entire duration of study participation unless she reports complete sexual abstinence. Female patients must not be pregnant or lactating
- Estimated creatinine clearance (eCrCl) ≥ 60 ml/min/1.73m2 calculated by Cockcroft-Gault method at screening
- Liver function tests ≤ 3X ULN for AST, ALT and total bilirubin; ≤ 3X ULN for ALP and GGT; and ≤ 3X ULN for CK at screening
- All other clinical laboratory parameters must be within normal limits or considered not clinically significant
- Electrocardiogram (ECG) must be normal, or if abnormal, considered not clinically significant at screening
- Systolic blood pressure ≤ 160 mm Hg and diastolic blood pressure ≤ 90 mm Hg at screening; known hypertensive patients stable (blood pressure [BP] reading as above) with medication may be included
- Patients using agents known to influence sUA levels (see Appendix 7) must be on a stable dose and regimen for at least two weeks prior to screening and must be willing to continue the same doses and regimens during study participation
- Expected to be able to tolerate a short course of either oral NSAIDs and/or oral steroids as may be needed to treat a flare
- Must be able to swallow tablets/capsules
- Following training, must be willing and able to understand and complete an electronic diary
Exclusion Criteria:
- Receiving treatment with allopurinol, colchicine, probenecid, benzbromarone, or febuxostat within two weeks or pegloticase within six months prior to screening
- Known or suspected secondary hyperuricemia (e.g. due to myeloproliferative disorder or organ transplant)
- Diagnosis of xanthinuria
- Fractional excretion of urate > 10% at screening
- History of documented or suspected kidney stones
- Known infection with the human immunodeficiency virus (HIV) or history of viral hepatitis type B or C
- A diagnosis of illicit drug or alcohol dependence or abuse within one year of screening
- History of upper gastrointestinal (GI) bleeding, documented peptic ulcer disease (unless known H. pylori infection treated successfully without recurrence), within three years of screening
- History of stroke, transient ischemic attack (TIA), acute myocardial infarction (MI), congestive heart failure (NYHA Class II-IV), angina pectoris, coronary intervention procedure (including but not limited to angioplasty, stent placement, coronary revascularization), lower extremity bypass procedure, systemic or intracoronary fibrinolytic therapy within five years of screening
- History of cancer within five years of screening, with the following exceptions: adequately treated non-melanomatous skin cancers, non-metastatic prostate cancer or in situ cervical cancer
- Patients with a history of bladder cancer, active bladder cancer or hematuria
- Body mass index (BMI) > 42 kg/m2 at screening
- Current or expected requirement for anticoagulant therapy (except for aspirin ≤ 325 mg/day, clopidogrel [Plavix] ≤ 75 mg/day, or prasugrel [Effient] ≤ 10 mg/day)
- Use of any of the following within eight weeks prior to screening: potent CYP3A4 inhibitors, cytotoxic agents (including azathioprine, mercaptopurine, cyclosporine, cyclophosphamide, etc.), ranolazine, digoxin, theophylline, sulphonylureas, thiazolidinediones (e.g., rosiglitazone or pioglitazone), atypical antipsychotic agents, ampicillin, amoxicillin, loop diuretics or phenytoin
- Chronic treatment with NSAIDs (except for as needed [prn] use to treat acute events); per protocol a short course of oral NSAIDs may be used to treat flares during the study
- Current or expected chronic treatment with systemic corticosteroids (topical, ophthalmic, intra-articular or inhaled corticosteroid at a dose < 1600 μg/day is permitted); per protocol a short course of oral corticosteroid may be used to treat flares occurring during the study
- History of intra-articular steroid injection to treat flare within four weeks of screening
- Known hypersensitivity or intolerance to allopurinol or colchicine
- Treatment with any other investigational therapy within 30 days or within five half lives, whichever is longer, prior to screening
- Patients who received arhalofenate in a previous trial
- Any other condition(s) that would compromise the safety of the patient, prevent compliance with the study protocol including ability to use an electronic diary, or compromise the quality of the clinical study, as judged by the Investigator and/or Medical Monitor
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Placebo tablets once daily for 12 weeks
|
Experimental: Arhalofenate 600 mg
|
Arhalofenate 600 mg tablets once daily for 12 weeks
|
Experimental: Arhalofenate 800 mg
|
Arhalofenate 800 mg tablets once daily for 12 weeks
|
Active Comparator: Allopurinol 300 mg; colchicine 0.6 mg
|
Allopurinol 300 mg tablets once daily for 12 weeks
Colchicine 0.6 mg over-encapsulated tablets once daily for 12 weeks
|
Active Comparator: Allopurinol 300 mg
|
Allopurinol 300 mg tablets once daily for 12 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The incidence of flares (mean number of flares per patient) from baseline through Week 12 in the arhalofenate 800 mg group compared to the allopurinol 300 mg group.
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percent sUA reduction from baseline to Week 12 in the arhalofenate 800 mg group compared to the placebo group
Time Frame: 12 weeks
|
12 weeks
|
Percent sUA reduction from baseline to Week 12 in the arhalofenate 600 mg group compared to the placebo group
Time Frame: 12 weeks
|
12 weeks
|
Proportion of patients with sUA < 6 mg/dL at Week 12 in the arhalofenate 800 mg group compared to the placebo group
Time Frame: 12 weeks
|
12 weeks
|
The incidence of flares from baseline through Week 12 in the arhalofenate 600 mg group compared to the allopurinol 300 mg group
Time Frame: 12 weeks
|
12 weeks
|
Proportion of patients with sUA < 6 mg/dL at Week 12 in the arhalofenate 600 mg group compared to placebo group
Time Frame: 12 weeks
|
12 weeks
|
Time from baseline to onset of first flare for the arhalofenate 800 mg group compared to the allopurinol 300 mg group
Time Frame: 12 weeks
|
12 weeks
|
Time from baseline to onset of first flare for the arhalofenate 600 mg group compared to the allopurinol 300 mg group
Time Frame: 12 weeks
|
12 weeks
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of patients experiencing at least one flare from baseline through Week 12
Time Frame: 12 weeks
|
12 weeks
|
Proportion of patients experiencing two or more flares from baseline through Week 12
Time Frame: 12 weeks
|
12 weeks
|
The incidence of flares from baseline through Week 4, from Week 5 through Week 8, and from Week 9 through Week 12
Time Frame: 12 weeks
|
12 weeks
|
Duration of flares
Time Frame: 12 weeks
|
12 weeks
|
Duration of flare treatment
Time Frame: 12 weeks
|
12 weeks
|
Flare composite score (summation of the daily maximum pain score on NRS during the duration of the flare)
Time Frame: 12 weeks
|
12 weeks
|
Proportion of patients experiencing flares who reached a sUA target < 6 mg/dL during treatment
Time Frame: 12 weeks
|
12 weeks
|
Evaluation of activity limitation associated with flare via HAQ-II
Time Frame: 12 weeks
|
12 weeks
|
Changes from baseline in fractional excretion of urate
Time Frame: 12 weeks
|
12 weeks
|
Changes from baseline in HbA1c and fasting TG in patients with HbA1c > 7.0% and TG > 150 mg/dL at baseline, respectively
Time Frame: 12 weeks
|
12 weeks
|
Adverse events (AE), and changes in vital signs and safety laboratory tests
Time Frame: 12 weeks
|
12 weeks
|
Safety-related study drug discontinuations
Time Frame: 12 weeks
|
12 weeks
|
Flare-related study drug discontinuations
Time Frame: 12 weeks
|
12 weeks
|
Steady-state arhalofenate acid serum and urine concentrations
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2014
Primary Completion (Actual)
January 1, 2015
Study Completion (Actual)
January 1, 2015
Study Registration Dates
First Submitted
February 12, 2014
First Submitted That Met QC Criteria
February 13, 2014
First Posted (Estimate)
February 17, 2014
Study Record Updates
Last Update Posted (Actual)
January 29, 2018
Last Update Submitted That Met QC Criteria
January 25, 2018
Last Verified
January 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Genetic Diseases, Inborn
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Arthritis
- Metabolism, Inborn Errors
- Crystal Arthropathies
- Purine-Pyrimidine Metabolism, Inborn Errors
- Gout
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Protective Agents
- Antioxidants
- Free Radical Scavengers
- Gout Suppressants
- Colchicine
- Allopurinol
Other Study ID Numbers
- CB102-21425
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gout
-
Ai PengRecruitingGout Flare | Intercritical Gout | Advanced Gout | Asymptomatic HyperuricemiaChina
-
AmgenCompletedUncontrolled Gout | Chronic GoutUnited States
-
Sheffield Hallam UniversityCherry Research CommitteeUnknown
-
Olatec Therapeutics LLCRecruitingArthritis | Joint Pain | Gout | Gout Flare | Gouty Arthritis | Acute Gout Flare | Gout AttackUnited States, Spain, France
-
GeneScience Pharmaceuticals Co., Ltd.Huashan HospitalNot yet recruitingAcute Gout | Gout Initiating Urico-lowering TherapyChina
-
GeneScience Pharmaceuticals Co., Ltd.Huashan HospitalRecruitingGout Flare | Acute GoutChina
-
AmgenCompletedGout | Chronic Uncontrolled Gout | Uncontrolled GoutUnited States
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingPrimary Gout With Hyperuricemia in Adults
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingPrimary Gout and Hyperuricemia
-
Guangdong Provincial Hospital of Traditional Chinese...RecruitingAcute Pain | Acupuncture | Acute Gout ArthritisChina
Clinical Trials on Arhalofenate 600 mg
-
KalVista Pharmaceuticals, Ltd.RecruitingHereditary AngioedemaUnited States, Bulgaria, France, Greece, Israel, Netherlands, Spain, United Kingdom, Australia, Germany, South Africa, Slovakia, Austria, New Zealand, Romania, Canada, Japan
-
Galapagos NVPRA Health SciencesCompleted
-
Spinifex Pharmaceuticals Pty LtdSyneos HealthWithdrawnNeuralgia, Postherpetic
-
AbbVieCompletedUlcerative Colitis (UC)United States, Canada, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Spain, United Kingdom
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.CompletedAsthma; Allergic RhinitisChina
-
MedImmune LLCCompletedChronic Obstructive Pulmonary DiseaseUnited States, Bulgaria, Czech Republic, Poland, United Kingdom, Philippines, Latvia, Lithuania, Ukraine, Hungary
-
Guangdong Raynovent Biotech Co., LtdCompleted
-
Zero Point Five TherapeuticsNot yet recruitingSoil-Transmitted Helminthiasis (STH)Brazil, Ghana
-
Altavant Sciences GmbHCovance; Altavant Sciences, Inc.Completed
-
PfizerCompleted